LifeStance Health Group, Inc. (NASDAQ:LFST) Receives $9.00 Average Target Price from Analysts

LifeStance Health Group, Inc. (NASDAQ:LFST) has been given a consensus recommendation of “Moderate Buy” by the nine research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $9.00.

LFST has been the topic of a number of analyst reports. BMO Capital Markets initiated coverage on shares of LifeStance Health Group in a research report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price target on the stock. UBS Group lifted their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a report on Thursday, November 13th. Wall Street Zen downgraded LifeStance Health Group from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, Zacks Research lowered LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th.

Institutional Trading of LifeStance Health Group

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in LifeStance Health Group by 19.5% in the third quarter. Vanguard Group Inc. now owns 14,613,535 shares of the company’s stock valued at $80,374,000 after buying an additional 2,383,728 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in LifeStance Health Group by 27.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after acquiring an additional 1,790,694 shares in the last quarter. Jennison Associates LLC boosted its stake in LifeStance Health Group by 2.1% in the 1st quarter. Jennison Associates LLC now owns 8,255,236 shares of the company’s stock worth $54,980,000 after purchasing an additional 168,856 shares during the period. Wellington Management Group LLP boosted its stake in LifeStance Health Group by 2.3% in the 1st quarter. Wellington Management Group LLP now owns 5,399,293 shares of the company’s stock worth $35,959,000 after purchasing an additional 123,056 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in LifeStance Health Group by 62.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after purchasing an additional 1,839,465 shares in the last quarter. 85.50% of the stock is owned by institutional investors.

LifeStance Health Group Stock Performance

Shares of LifeStance Health Group stock opened at $6.20 on Friday. The firm has a fifty day moving average of $5.42 and a two-hundred day moving average of $5.25. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of -206.67 and a beta of 1.15. LifeStance Health Group has a 52 week low of $3.74 and a 52 week high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The business had revenue of $363.81 million during the quarter, compared to analysts’ expectations of $355.06 million. During the same period in the previous year, the firm earned ($0.02) earnings per share. The firm’s quarterly revenue was up 16.3% compared to the same quarter last year. LifeStance Health Group has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts predict that LifeStance Health Group will post -0.18 EPS for the current year.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.